辽宁成大(600739) - 2025 Q2 - 季度业绩预告

Core Performance Forecast The company forecasts a substantial increase exceeding 50% in both net profit attributable to shareholders and non-recurring net profit for H1 2025, indicating robust core business profitability 2025 Half-Year Performance Forecast | Metric | Estimated Amount (million CNY) | YoY Growth (%) | | :--- | :--- | :--- | | Net Profit Attributable to Parent Company Shareholders | 689.16 - 735.10 | 50.00 - 60.00 | | Net Profit Attributable to Parent Company Shareholders After Non-Recurring Items | 684.13 - 735.07 | 50.30 - 61.50 | - This performance forecast represents the company's preliminary estimation based on operational conditions, unaudited by a certified public accountant[3] Review of Prior Period Performance The report provides 2024 prior period financial data as a comparative baseline, showing net profit attributable to shareholders at CNY 459.44 million and non-recurring net profit at CNY 455.16 million 2024 Half-Year (Prior Period) Performance | Metric | Amount (million CNY) | | :--- | :--- | | Total Profit | 492.72 | | Net Profit Attributable to Parent Company Shareholders | 459.44 | | Net Profit Attributable to Parent Company Shareholders After Non-Recurring Items | 455.16 | | Earnings Per Share (CNY) | 0.3018 | Performance Growth Drivers Significant performance growth is primarily driven by increased investment income, attributed to the company's dual-driven strategy in healthcare and financial investments - The primary reason for the significant performance growth this period is the increase in the company's investment income[7] - The company diligently implements its dual-driven development strategy, focusing on 'pharmaceutical and healthcare industries alongside financial investments,' maintaining steady progress to enhance operational quality and efficiency[7] Risk Warning and Other Notes This performance forecast is based on unaudited preliminary calculations, with final data subject to the officially disclosed half-year report, cautioning investors on investment risks - The data in this performance forecast represents preliminary results based on the company's finance department's professional judgment, unaudited[8] - Final performance data will be subject to the company's officially disclosed 2025 half-year report, reminding investors to be aware of investment risks[9]